FKBP1A and cancer: Furthermore, we propose a therapeutic approach to bypass ERFE-mediated BMP resistance by displacing the inhibitor FKBP12 from the BMPR-I with FK506 (tacrolimus), in models of cancer cachexia in vitro and in vivo.